Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. Primary invasive breast carcinoma confirmed by core needle biopsy of the breast lesion.
2. Clinical stage cT1-4N0-3M0.
3. Age 18 to 70 years.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
5. Hepatic, renal, and cardiac function adequate to tolerate chemotherapy and targeted therapy, as applicable.
6. Planned neoadjuvant chemotherapy with or without targeted therapy.
7. Provision of informed consent before study participation.
You may not be if
1. Pregnancy or breastfeeding.
2. Previous surgery or radiotherapy involving the ipsilateral axillary lymph nodes.
3. Diabetes mellitus or allergy to the radiotracer rendering the patient unsuitable for 18F-FDG PET/CT examination.
4. A history of, or concurrent, malignancy other than breast cancer, except non-melanoma skin cancer, carcinoma in situ of the cervix, or another malignancy considered cured with no evidence of recurrence for at least 5 years.
Psychiatric illness or another condition affecting compliance with study requirements.
5. Serious disease or medical conditions, including:- Congestive heart failure, unstable angina, myocardial infarction within 6 months before enrollment, hypertension considered uncontrolled by the investigator, or high-risk uncontrolled arrhythmia.
* Significant neurological or psychiatric disorders that may impair understanding or provision of informed consent.
* Uncontrolled acute infection.
6. An allergic predisposition or known or suspected allergy to any study medication.
7. Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.
Clareo Health | MAMMI-BB PET for Monitoring Response to Neoadjuvant Therapy in Breast Cancer
